Changing the Rules

Changing the Rules

As revealed at the recent Association for Research in Vision

and Ophthalmology (ARVO 2021) Virtual Meeting, there is a new superhero in town.

 And, suddenly, the rules of intraocular pressure (IOP) management in glaucoma have changed.

 Netarsudil — a rho-kinase inhibitor that targets the trabecular outflow pathway — has been a gamechanger in reducing elevated IOP in patients with glaucoma or ocular hypertension (OHT).

 Netarsudil: Setting new rules in glaucoma management According to Dr. Casey Kopczynski, chief scientific officer at Aerie Pharmaceuticals: ลาวสามัคคี วีไอพี

“Netarsudil represents the first new glaucoma drug class to be approved in the U.S. in over 20 years.

In phase 3 trials, once-daily netarsudil demonstrated consistent and sustained IOP lowering, with tolerable ocular safety through 12 months.” Either alone or in a team, netarsudil gets the job done.

“In 2019, netarsudil/ latanoprost 0.02%/0.005% fixeddose combination (FDC) received FDA approval for the same indication, becoming

the first FDC in the U.S. to contain a prostaglandin analog,” shared Dr. Kopczynski.

“In phase 3 trials, once-daily netarsudil/latanoprost FDC demonstrated significantly greater IOP lowering than both latanoprost

and netarsudil as monotherapy at all time points over 3 months with tolerable ocular safety through 12 months.”

Post-approval, netarsudil continues its trailblazing performance.

“In the phase 4 MOST study, a prospective, randomized, multi-center, noncomparator study conducted

in a realworld setting, use of netarsudil either as the first addition to prostaglandin therapy, or as a third or fourth addition to existing therapy provided an additional 4.3

and 4.5mmHg IOP reduction, respectively, and was generally well-tolerated,” added Dr. Kopczynski.

Dr. Kopczynski explained that netarsudil appears to lower IOP through a dual mechanism of action

by reducing the profibrotic activity of rho kinase at the trabecular meshwork while simultaneously reducing episcleral venous pressure.

“The clinical studies conducted to date show that netarsudil’s unique mechanism of action provides an equally impressive efficacy profile with several benefits for glaucoma patients,” he concluded.

For more information: ลาวสามัคคี วีไอพี